CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients ...

The 3475A-D77 trial, which was presented at the European Lung Cancer Congress (ELCC), showed that the subcutaneous ...

The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the landscape of Alzheimer’s disease treatments. For the first time, patients have the option to take a drug ...

Entyvio’s dosage is an intravenous (IV) infusion every 8 weeks or a subcutaneous injection every 2 weeks. The starting dosage is two infusions 2 weeks apart. After that, you’ll continue with ...